Amgen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

03.08.22	AMGEN APPOINTS MICHAEL V. DRAKE TO BOARD OF DIRECTORS (PR Newswire)
03.08.22	AMGEN ANNOUNCES 2022 THIRD QUARTER DIVIDEND (PR Newswire)
02.08.22	AMGEN TO WEBCAST INVESTOR MEETING AT WCLC 2022 (PR Newswire)
01.08.22	AMGEN ANNOUNCES WEBCAST OF 2022 SECOND QUARTER FINANCIAL RESULTS (PR Newswire)
25.07.22	AstraZeneca: CHMP Recommends Tezspire For Severe Asthma In EU (RTTNews)
20.06.22	AMGEN FOUNDATION MORE THAN DOUBLES COMMITMENT TO LABXCHANGE, FREE VIRTUAL SCIENCE EDUCATION PLATFORM (PR Newswire)
10.06.22	AMGEN ANNOUNCES WEBCAST OF GOLDMAN SACHS 43RD ANNUAL HEALTHCARE CONFERENCE (PR Newswire)
06.06.22	Amgen: FDA Approves RIABNI For Adults With Moderate To Severely Active Rheumatoid Arthritis (RTTNews)
06.06.22	FDA APPROVES RIABNI™ (RITUXIMAB-ARRX), A BIOSIMILAR TO RITUXAN® (RITUXIMAB), FOR ADULTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS (PR Newswire)
05.06.22	NEW HEAD-TO-HEAD DATA SHOW VECTIBIX® (PANITUMUMAB) DEMONSTRATED SUPERIOR OVERALL SURVIVAL COMPARED TO BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN JAPANESE PATIENTS WITH WILD-TYPE RAS COLORECTA... (PR Newswire)
03.06.22	AMGEN ANNOUNCES WEBCAST OF 2022 JEFFERIES HEALTHCARE CONFERENCE (PR Newswire)
31.05.22	Amgen Positive Topline Data In Phase 2 Trial For Olpasiran In Adults With Elevated Lipoprotein (RTTNews)
31.05.22	AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 2 DATA FOR INVESTIGATIONAL OLPASIRAN IN ADULTS WITH ELEVATED LIPOPROTEIN(a) (PR Newswire)
26.05.22	NEW DATA SHOWCASES HOW AMGEN IS ADVANCING ALL ANGLES OF CANCER CARE THROUGH INNOVATIVE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2022 (PR Newswire)
12.05.22	AMGEN AND LANCE BASS PARTNER TO ENCOURAGE PEOPLE TO DO A 'DOUBLE TAKE' TO RECOGNIZE THE EARLY SIGNS OF PSORIATIC ARTHRITIS (PR Newswire)
06.05.22	AMGEN ANNOUNCES WEBCAST OF 2022 BANK OF AMERICA HEALTHCARE CONFERENCE (PR Newswire)
02.05.22	AMGEN RELEASES ANNUAL ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT (PR Newswire)
27.04.22	Amgen Inc. Q1 Profit Decreases, but beats estimates (RTTNews)
27.04.22	AMGEN REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS (PR Newswire)
27.04.22	AMGEN ANNOUNCES RESULTS FROM TWO OPEN LABEL EXTENSION STUDIES OF REPATHA® (EVOLOCUMAB) (PR Newswire)
22.04.22	AMGEN ANNOUNCES WEBCAST OF 2022 FIRST QUARTER FINANCIAL RESULTS (PR Newswire)
18.04.22	AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 654, BIOSIMILAR CANDIDATE TO STELARA® (USTEKINUMAB) (PR Newswire)
10.04.22	LUMAKRAS® (SOTORASIB) CODEBREAK 100 STUDY SHOWS TWO-YEAR OVERALL SURVIVAL OF 32.5% IN PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER (PR Newswire)
25.03.22	AMGEN ANNOUNCES NEW OTEZLA (APREMILAST) DATA AT AAD CONGRESS 2022 (PR Newswire)
10.03.22	Amgen To Present At The 32nd annual Oppenheimer Healthcare Conference (PR Newswire)
08.03.22	AMGEN TO PRESENT LONG-TERM OUTCOMES FOR LUMAKRAS® (SOTORASIB) IN KRAS G12C-MUTATED NSCLC AT AACR 2022 (PR Newswire)
07.03.22	GLOBAL BIOTECHNOLOGY LEADER AMGEN BREAKS GROUND ON NEW MANUFACTURING FACILITY IN NORTH CAROLINA (PR Newswire)
02.03.22	AMGEN TO PRESENT AT THE 42ND ANNUAL COWEN HEALTHCARE CONFERENCE (PR Newswire)
02.03.22	AMGEN ANNOUNCES 2022 SECOND QUARTER DIVIDEND (PR Newswire)
26.02.22	NEW DATA FURTHER REINFORCE EFFICACY OF TEZSPIRE™ (TEZEPELUMAB-EKKO) IN A BROAD POPULATION OF SEVERE ASTHMA PATIENTS (PR Newswire)
22.02.22	AMGEN ISSUES INAUGURAL GREEN BOND TO ADVANCE ESG GOALS (PR Newswire)
16.02.22	AMGEN RECOGNIZED FOR OUTSTANDING ESG PERFORMANCE (PR Newswire)
14.02.22	LUMAKRAS® (SOTORASIB) SHOWS ENCOURAGING AND CLINICALLY MEANINGFUL ANTICANCER ACTIVITY IN PATIENTS WITH KRAS G12C-MUTATED ADVANCED PANCREATIC CANCER IN CODEBREAK 100 TRIAL (PR Newswire)
08.02.22	AMGEN OUTLINES GROWTH STRATEGY THROUGH 2030 AT VIRTUAL BUSINESS REVIEW (PR Newswire)
08.02.22	Amgen Issues FY22 & Long-term Guidance - Quick Facts (RTTNews)
08.02.22	AMGEN PROVIDES LONG-TERM GUIDANCE THROUGH 2030 DURING BUSINESS REVIEW MEETING (PR Newswire)
07.02.22	Amgen Inc. Q4 Profit Increases, beats estimates (RTTNews)
07.02.22	AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS (PR Newswire)
03.02.22	AMGEN TO HOST VIRTUAL BUSINESS REVIEW MEETING (PR Newswire)
03.02.22	Amgen, Plexium Collaborate To Identify Novel Targeted Protein Degradation Therapies (RTTNews)
03.02.22	AMGEN AND PLEXIUM ANNOUNCE MULTI-YEAR, DRUG DISCOVERY COLLABORATION TO IDENTIFY NOVEL TARGETED PROTEIN DEGRADATION THERAPIES (PR Newswire)
20.01.22	LUMAKRAS® (SOTORASIB) RECEIVES APPROVAL IN JAPAN FOR PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER (PR Newswire)
13.01.22	AstraZeneca, Amgen Announce Market Availability Of Tezspire - Quick Facts (RTTNews)
13.01.22	TEZSPIRE™ (TEZEPELUMAB-EKKO) NOW AVAILABLE IN THE UNITED STATES FOR THE TREATMENT OF SEVERE ASTHMA (PR Newswire)
11.01.22	Amgen, Arrakis Collaborate To Discover RNA Degrader Small Molecule Therapeutics (RTTNews)
11.01.22	AMGEN AND ARRAKIS THERAPEUTICS ANNOUNCE MULTI-TARGET COLLABORATION TO IDENTIFY NOVEL RNA DEGRADER SMALL MOLECULE THERAPEUTICS (PR Newswire)
10.01.22	EUROPEAN COMMISSION APPROVES LUMYKRAS® (SOTORASIB) FOR PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER (PR Newswire)
06.01.22	AMGEN TO PRESENT AT THE 40TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE (PR Newswire)
06.01.22	AMGEN AND GENERATE BIOMEDICINES ANNOUNCE MULTI-TARGET, MULTI-MODALITY RESEARCH COLLABORATION AGREEMENT (PR Newswire)
23.12.21	AMGEN TO PRESENT AT THE GOLDMAN SACHS 14TH ANNUAL HEALTHCARE CEOS UNSCRIPTED CONFERENCE (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

20.12.24		Handel in New York: Am Freitagnachmittag Gewinne im Dow Jones
20.12.24		Verluste in Europa: Euro STOXX 50 letztendlich leichter
20.12.24		Dow Jones aktuell: Dow Jones fällt zum Start des Freitagshandels zurück
20.12.24		NASDAQ-Handel NASDAQ 100 schwächelt zum Start des Freitagshandels
20.12.24		Börse Frankfurt: So steht der LUS-DAX am Nachmittag
20.12.24		Börse Frankfurt: DAX präsentiert sich nachmittags leichter
20.12.24		Zurückhaltung in Europa: Euro STOXX 50 präsentiert sich schwächer
20.12.24		Wechsel bei Sanofi: Ex-Morphosys-Chef Kress tritt in den Verwaltungsrat ein -Sanofi-Aktie tiefer

20.12.24

Handel in New York: Am Freitagnachmittag Gewinne im Dow Jones

20.12.24

Verluste in Europa: Euro STOXX 50 letztendlich leichter

20.12.24

Dow Jones aktuell: Dow Jones fällt zum Start des Freitagshandels zurück

20.12.24

NASDAQ-Handel NASDAQ 100 schwächelt zum Start des Freitagshandels

20.12.24

Börse Frankfurt: So steht der LUS-DAX am Nachmittag

20.12.24

Börse Frankfurt: DAX präsentiert sich nachmittags leichter